



Experience
INDIAN
HEALTHCARE

Poly Medicure Ltd.

POLYMED
Medical Devices

Regd. Office : 232-B, 3rd Floor, Okhla Industrial Estate, Phase - III, New Delhi - 110020, INDIA
Tel : +91-11-47317000, 33550700, 26321838 / 81 / 89 / 93 / 99, Fax : +91-11-26321894, 26321839
E-mail : info@polymedicure.com Website : www.polymedicure.com
CIN : L40300DL1995PLC066923

Dated: 01st August, 2018

Scrip Code : 531768

Scrip Code : POLYMED

The Manager,
Department of Corporate Services,
Bombay Stock Exchange Limited
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai-400001.

The Manager,
Department of Corporate Services,
National stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G- Block
Bandra Kurla Complex, Bandra (E), Mumbai-400051

Subject: Outcome of Board Meeting of the Company

Ref: Compliance of Regulation 30 and 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 and 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform the Stock Exchange that, the Board of Directors at their meeting held today i.e. 01st August, 2018 at Crowne Plaza Hotels, Community Centre, Okhla Industrial Estate, Phase – I, New Delhi-110020 has approved.

- Un-Audited Financial Results along with Limited Review Report for the First Quarter ended on 30th June, 2018.
- Allotment of Equity Shares under ESOS 2015.
- Other Normal Businesses

Kindly acknowledge the receipt of the same.

Thanking You,

For Poly Medicure Limited

Avinash Chandra
Company Secretary



(Rs. In Lacs)

		Quarter Ended			Year Ended
		30.06.2018	31.03.2018	30.06.2017	31.03.2018
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income				
a	Revenue from Operations	13,136.74	14,036.22	10,866.45	50,969.93
b	Other income	333.27	465.93	364.71	1,436.95
	Total income	13,470.01	14,502.15	11,231.16	52,406.88
2	Expenses				
a	Cost of materials consumed	4,255.20	4,553.57	3,786.37	16,713.93
b	Purchases of stock-in-trade	16.63	133.75	113.41	437.26
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(298.01)	109.95	(710.69)	(994.00)
d	Excise Duty on Sales	-	0.00	126.10	126.10
e	Employee benefits expense	2,602.30	2,464.57	2,117.73	9,392.66
f	Research and development expenses	293.34	271.77	244.69	1,004.78
g	Finance cost	381.02	321.79	210.65	949.51
h	Depreciation and amortisation expense	859.64	786.81	653.69	2,840.66
i	Other expenses	3,138.35	3,206.93	2,873.45	12,300.39
	Total expenses	11,248.47	11,849.14	9,415.38	42,771.29
3	Profit from operations before exceptional items (1-2)	2,221.54	2,653.01	1,815.78	9,635.59
4	Exceptional Items				
5	Profit before tax	2,221.54	2,653.01	1,815.78	9,635.59
6	Tax expense				
a	Current tax	695.78	279.06	668.02	2,536.55
b	Deferred tax	170.38	106.03	(54.39)	79.21
c	Earlier Year Taxes	(6.66)	(37.65)	-	0.00
	Total Tax Expense	859.50	347.44	613.63	2,615.76
7	Profit for the period	1,362.04	2,305.57	1,202.15	7,019.83
8	Other Comprehensive Income				
	Items that will not be reclassified to profit or loss :				
	Remeasurements of defined benefit obligations	9.91	18.14	(7.63)	40.77
	Tax impacts on above	(3.46)	(6.28)	2.64	(14.11)
	Total Other Comprehensive Income	6.45	11.86	(4.99)	26.66
9	Total comprehensive income (comprising profit after tax and other comprehensive income after tax for the period)	1,368.49	2,317.43	1,197.16	7,046.49
10	Paid-up equity share capital (Face Value of ₹ 5 each)	4,411.34	4,411.34	4,411.34	4,411.34
11	Earnings per share (Not annualised) :				
	Basic (₹)	1.54	2.61	1.36	7.96
	Diluted (₹)	1.54	2.61	1.36	7.95




Munish



Notes:

- 1 The above results were reviewed and recommended by the Audit Committee & approved by the Board of Directors at their respective meetings held on 1st August 2018. The Statutory auditors have conducted a limited review of the above Financial Results.
- 2 The figures for last quarter of the previous year are the balancing figures between audited figures in respect of full financial year and the published figures for nine months ended for respective year.
- 3 Post applicability of Goods and Services Tax (GST) w.e.f. 1st July 2017, Revenue from Operations are required to be disclosed net of GST in accordance with the requirements of Ind AS. Accordingly, the Revenue from Operations for the quarter ended 30th June 2018 is not comparable with corresponding quarter of the previous year presented in the financial results which is reported inclusive of Excise Duty.
- 4 In line with the provisions of Ind AS 108 – Operating Segments and on the basis of review of operations being done by the management of the Company, the operations of the group falls under medical devices, which is considered to be the only reportable segment by the management.
- 5 Ind AS 115 "Revenue from Contracts with customers", mandatory for reporting periods beginning on or after April 1, 2018, replaces existing revenue recognition requirements. Under the modified retrospective approach, there were no significant adjustment required to the retained earnings as at April 1, 2018. Also, the application of Ind AS 115 did not have any significant impact on recognition and measurement of revenue and related items in the financial results of the company.
- 6 The Company has opted to publish standalone financial results for the quarter ended 30th June 2018 and the consolidated financial results shall be published for the quarter / year ending 31st March 2019.
- 7 The standalone unaudited financial results of the Company for the quarter ended 30th June 2018 are also available on the Company's Website (www.polymedicure.com) and on the Website of BSE (www.bseindia.com) and NSE (www.nseindia.com) in accordance with the provisions of (Listing obligations and Disclosure Requirements) Regulations, 2015.

Place : New Delhi
Date : 01.08.2018



Himanshu Bald
Himanshu Bald
Managing Director





POLY MEDICURE LIMITED

Regd. Office: 232B, 3rd Floor, Okhla Industrial Estate Phase III, New Delhi - 110 020,
Phone: 011-26321889, Fax: 011-26321894

Website: www.polymedicure.com, E-mail: investorcare@polymedicure.com, CIN: L40300DL1995PLC066923
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2018

		(Rs. In Lacs)			
		Quarter Ended		Year Ended	
		30.06.2018	31.03.2018	30.06.2017	31.03.2018
		Unaudited	Audited	Unaudited	Audited
1	Total Income from operations	13,470.01	14,502.15	11,231.16	52,406.88
2	Net Profit from ordinary activities after tax	1,362.04	2,305.57	1,202.15	7,019.83
3	Net Profit for the period after tax (after Extraordinary items)	1,362.04	2,305.57	1,202.15	7,019.83
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	1,368.49	2,317.43	1,197.16	7,046.49
5	Equity paid up share capital	4,411.34	4,411.34	4,411.34	4,411.34
6	Earnings per share (Not annualised) :				
	Basic (₹)	1.54	2.61	1.36	7.96
	Diluted (₹)	1.54	2.61	1.36	7.95

- 1 The above results were reviewed and recommended by the Audit Committee & approved by the Board of Directors at their respective meetings held on 1st August 2018. The Statutory auditors have conducted a limited review of the above Financial Results.
- 2 The above is an extract of the detailed format of standalone Quarterly Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the unaudited standalone Financial Results are available on the Stock Exchange websites, www.bseindia.com, www.nseindia.com and on the company website www.polymedicure.com.

Place : New Delhi
Date : 01.08.2018



Himanshu Baid
Managing Director

DOOGAR & ASSOCIATES

Chartered Accountants

To Board of Directors
Poly Medicare Limited
232-B, IIIrd Floor,
Okhla Industrial Estate, Phase-III,
New Delhi- 110020


We have reviewed the accompanying statement of unaudited standalone financial results of Poly Medicare Limited ("the company") for the quarter ended 30th June, 2018 attached herewith, being submitted by the company pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). This statement is the responsibility of the Company's Management and approved by the Board of Directors has been compiled from the related interim financial statements which has been prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Doogar & Associates
Chartered Accountants
Firm Registration No. 000561N



M. S. Agarwal
Partner
Membership No. 086580



Place of signature: New Delhi
Date: 01st August 2018